BioIndustry Association Applauds Continued Funding of Biomedical Catalyst
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
26 June 2013 -- The BioIndustry Association (BIA) applauds the Chancellor's announcement in the Spending Review 2015-16 to provide additional resource funding of £185 million for the Technology Strategy Board (TSB) to support innovation, including Catapult Centres and the Biomedical Catalyst.
Steve Bates, BIA Chief Executive Officer, said:
"The BIA is delighted that the government will continue to support the Biomedical Catalyst, one of the key measures in its Strategy for UK Life Sciences, which has been warmly received across the sector.
"I am meeting with the TSB next week to understand the details of how this funding will be scheduled and allocated." The BIA is also pleased to see that government will maintain resource funding for science in cash terms at £4.6 billion in 2015-16 and increase science capital funding in real terms from £0.6 billion in 2012-13 to £1.1 billion in 2015-16, and in line with inflation to 2016-17.
For further information, please contact Robert Winder, Head of Communications, rwinder@bioindustry.org, 020 7630 2191; mobile 07825 942 934.
BIA Biomedical Catalyst report
http://bit.ly/BIA_bmcreport
BIA Biomedical Catalyst campaign
The BIA has led the campaign for the government to re-fill the Biomedical Catalyst http://bit.ly/11Rp3DU
BioIndustry Association
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Help employers find you! Check out all the jobs and post your resume.
26 June 2013 -- The BioIndustry Association (BIA) applauds the Chancellor's announcement in the Spending Review 2015-16 to provide additional resource funding of £185 million for the Technology Strategy Board (TSB) to support innovation, including Catapult Centres and the Biomedical Catalyst.
Steve Bates, BIA Chief Executive Officer, said:
"The BIA is delighted that the government will continue to support the Biomedical Catalyst, one of the key measures in its Strategy for UK Life Sciences, which has been warmly received across the sector.
"I am meeting with the TSB next week to understand the details of how this funding will be scheduled and allocated." The BIA is also pleased to see that government will maintain resource funding for science in cash terms at £4.6 billion in 2015-16 and increase science capital funding in real terms from £0.6 billion in 2012-13 to £1.1 billion in 2015-16, and in line with inflation to 2016-17.
For further information, please contact Robert Winder, Head of Communications, rwinder@bioindustry.org, 020 7630 2191; mobile 07825 942 934.
BIA Biomedical Catalyst report
http://bit.ly/BIA_bmcreport
BIA Biomedical Catalyst campaign
The BIA has led the campaign for the government to re-fill the Biomedical Catalyst http://bit.ly/11Rp3DU
BioIndustry Association
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Help employers find you! Check out all the jobs and post your resume.